PeptideStack
5.2kquestions
20kanswers
220users

Does holding at 30 mg for sixteen weeks before escalating reduce fatigue?

Asked 10 May 2024Modified 2.2 years agoViewed 40k times
28

Details up front: 30 mg · sixteen weeks · fatigue.

I can predict the outcome but I cannot explain it, which means I will get the next case wrong.

I would like to know how confident the field actually is about this.

Can someone derive this rather than assert it?

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questionsnausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questionsdose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

88 questions
shareeditfollowflag
PT
askedpascal_thibault13k2710 May 2024
Note that the label instructions differ between agents on precisely this point. – Dr_Bram_Verhoeven 33 days ago
add a comment

No answers yet

This question has not been answered. It has been viewed 40k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.